| 黄国政.瑞舒伐他汀联合依帕司他治疗2型糖尿病早期视网膜病变患者临床疗效观察及对D-二聚体、Hcy、VEGF、NES和IGF-1水平影响研究[J].浙江中西医结合杂志,2020,30(2): |
| 瑞舒伐他汀联合依帕司他治疗2型糖尿病早期视网膜病变患者临床疗效观察及对D-二聚体、Hcy、VEGF、NES和IGF-1水平影响研究 |
| Clinical observation of rosuvastatin combined with epalrestat in the treatment of early type 2 diabetic retinopathy and its effect on D-dimer, Hcy, VEGF, NES and IGF-1 levelsHuang Guozheng Leimei Hua Weng JunHua Huang Qinqin Medical Department of Jinhua Fifth Hospital 321000 |
| 投稿时间：2019-05-06 修订日期：2019-10-10 |
| DOI： |
| 中文关键词: 瑞舒伐他汀 依帕司他 2型糖尿病早期视网膜病变 疗效 D-二聚体 同型半胱氨酸 血管内皮生长因子 内抑素 胰岛素生长因子1 |
| 英文关键词:rosuvastatin epalrestat early retinopathy of type 2 diabetes mellitus efficacy D-dimer homocysteine vascular endothelial growth factor endostatin insulin growth factor 1 |
| 基金项目: |
|
| 摘要点击次数: 541 |
| 全文下载次数: 3 |
| 中文摘要: |
| 目的：探讨瑞舒伐他汀联合依帕司他治疗2型糖尿病早期视网膜病变患者疗效及对D-二聚体、同型半胱氨(Hcy)、血管内皮生长因子(VEGF)、内抑素(NES)和胰岛素生长因子1(IGF-1)水平影响研究。方法：收治的2型糖尿病早期视网膜病变患者94例,依据随机表法分为对照组47例与观察组47例。对照组采用依帕司他治疗,观察组在对照组基础上结合瑞舒伐他汀治疗。两组疗程均为12周。比较两组治疗疗效,治疗前后糖代谢指标、D-二聚体、Hcy、VEGF、NES和IGF-1水平,及药物不良反应情况。结果：两组治疗后FPG、HOMA-IR和HbA1c较治疗前降低(观察组：t=18.776、17.685、16.759,对照组：t=12.541、10.071、7.623,P<0.05)；观察组治疗后FPG、HOMA-IR和HbA1c低于对照组(t=8.734、8.597、13.104,P<0.05)。两组治疗后血浆D-二聚体、Hcy、VEGF和IGF-1水平较治疗前降低而NES水平较治疗前升高(观察组：t=12.072、13.564、22.585、15.067、43.584,对照组：t=5.801、9.176、11.609、7.512、11.609,P<0.05)；观察组治疗后血浆D-二聚体、Hcy、VEGF和IGF-1水平低于对照组而NES水平高于对照组(t=9.691、6.400、7.416、9.251、25.840,P<0.05)。观察组治疗总有效率(91.49%)高于对照组(70.21%)(P<0.05)。观察组不良反应发生率(8.51%)低于对照组(27.66%)(P<0.05)。结论：瑞舒伐他汀联合依帕司他治疗2型糖尿病早期视网膜病变患者疗效良好,且可降低D-二聚体、Hcy、VEGF和IGF-1水平,而提高NES水平,值得临床借鉴。 |
| 英文摘要: |
| Objective: To investigate the efficacy of rosuvastatin combined with epalrestat in the treatment of early retinopathy of type 2 diabetes mellitus and its effects on the levels of D-dimer, homocysteine (Hcy), vascular endothelial growth factor (VEGF), endostatin (NES) and insulin growth factor-1 (IGF-1). Methods: The 94 patients with early retinopathy of type 2 diabetes mellitus were divided into control group (47 cases) and observation group (47 cases) according to random table method. The control group was treated with epalrestat, while the observation group was treated with rosuvastatin on the basis of the control group. Both groups were treated for 12 weeks. The therapeutic efficacy, levels of glucose metabolism, D-dimer, Hcy, VEGF, NES and IGF-1, and adverse drug reactions were compared between the two groups before and after treatment. Results: After treatment, FPG, HOMA-IR and HbA1c in the two groups were lower than those before treatment (observation group:t=18.776, 17.685, 16.759, control group:t=12.541, 10.071, 7.623, P<0.05); after treatment, FPG, HOMA-IR and HbA1c in the observation group were lower than those in the control group (t=8.734, 8.597, 13.104, P<0.05). After treatment, plasma D-dimer, Hcy, VEGF and IGF-1 levels in the two groups were lower than those before treatment, while NES levels were higher than those before treatment (observation group:t=12.072, 13.564, 22.585, 15.067, 43.584, control group:t=5.801, 9.176, 11.609, 7.512, 11.609, P<0.05); After treatment, plasma D-dimer, Hcy, VEGF and IGF-1 levels in the observation group were lower than those in the control group, while NES levels were higher than those in the control group (t=9.691, 6.400, 7.416, 9.251, 25.840, P<0.05). The total effective rate of the observation group (91.49%) was higher than that of the control group (70.21%) (P<0.05). The incidence of adverse reactions in the observation group (8.51%) was lower than that in the control group (27.66%) (P<0.05). Conclusion: Rosuvastatin combined with epalrestat is effective in the treatment of early type 2 diabetic retinopathy, and can reduce the levels of D-dimer, Hcy, vascular endothelial growth factor and IGF-1, while improving the level of NES, which is worthy of clinical reference. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
